Abstract library

7 results for "Laca".
#253 Description and Treatment of GEP NETs in a Spanish Hospital During 10 Years
Introduction: In our area the GEP NET incidence is similar to that of gastric and exocrine pancreatic cancers consequently being important to know their characteristics and the most convenient therapeutic approach.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#257 Doxorubicin, Etoposide and Cisplatin as first-line Treatment in Advanced Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis in advanced setting due to its low chemosensibility. Mitotane and cisplatin-based regimens are the most frequently used treatments.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#705 A Multi-Center Retrospective Evaluation of Neuroendocrine Tumors (Anatolian Society of Medical Oncology Group Study)
Introduction: Neuroendocrine tumors (NETs) are uncommon malignancies.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D Halit Karaca
Authors: Karaca H, Erol O, Ulas A, Demirci U, ...
#1279 Epidemiology Survival and Prognosis of Neuroendocrine Tumors: A Multidisciplinary Single-Center Study
Introduction: There is no certain consensus about prognostic factors of NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Ersin Özaslan
#1379 Evaluation of the Concordance Between the Stage of the Disease and Ki-67 Proliferation Index in Gastroenteropancretic Neuroendocrine Tumors (GEP-NETs)
Introduction: .
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Ersin Özaslan
Authors: Özaslan E, Demir S, Karaca H, Güven K, ...
Keywords: grade, stage, NET
#1503 Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study
Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Roberto Buzzoni
#1568 Neuroendocrine Neoplasm of the Colon and Rectum, Pathological and Clinical Characteristics, Based on pTNM WHO 2010 Classification
Introduction: Large bowel neuroendocrine neoplasms (NENs)
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Jaroslaw Cwikła